Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)

Name: Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
Published: 2023
License: Public Domain

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

plasmodiumfalciparum polymerasechainreaction

acute malaria, m5717, plasmodium mutants, pyronaridine, plasmodium falciparum, polymerase chain reaction, adequate clinical and parasitological response, plasmodium eukaryotic translation elongation factor 2, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)

Related documents